cadonilimab + AK117 + oxaliplatin + docetaxel + 5-fluorouracil

A combination regimen of **cadonilimab** (a bispecific monoclonal antibody targeting PD-1 and CTLA-4), **AK117** (a humanized IgG4 anti-CD47 antibody), **oxaliplatin** (a platinum-based chemotherapeutic), **docetaxel** (a taxane-class cytotoxic agent), and **5-fluorouracil** (a pyrimidine analog anti-metabolite) primarily investigated in advanced or resectable, HER2-negative gastric or gastroesophageal junction adenocarcinoma. - **Mechanism:** - **Cadonilimab** blocks PD-1 and CTLA-4, enhancing T-cell–mediated anti-tumor activity (checkpoint inhibition). - **AK117** antagonizes CD47, disrupting CD47-SIRPα signaling, thereby promoting phagocytosis of tumor cells by macrophages. - **Oxaliplatin** forms DNA crosslinks, inhibiting DNA replication and transcription. - **Docetaxel** stabilizes microtubules, inhibiting cell division. - **5-fluorouracil** inhibits thymidylate synthase and incorporates into RNA/DNA, disrupting nucleic acid synthesis. - **Indication**: Investigated for first-line (1L), neoadjuvant, and advanced/metastatic gastric and gastroesophageal junction adenocarcinoma (HER2-negative). - **Developer:** Akeso for cadonilimab and AK117[1][4] - Chemotherapy agents (oxaliplatin, docetaxel, 5-fluorouracil) are developed and manufactured by multiple companies worldwide[2][5].